B2M and Alzheimer disease: Moreover, a retrospective analysis involving 245 subjects (including 45 mild cognitive impairment patients, 100 healthy individuals, and 100 AD patients) revealed that plasma B2M levels was increased in AD patients compared to both normal controls and mild cognitive impairment (MCI) patients (Dominici et al. 2018).